Seres Therapeutics expects cash to fund operations into Q1 2026

As of June 30, 2025, Seres had $45.4 million in cash and cash equivalents. Based on the Company’s current cash position, the $25 million installment payment received from Nestle in July 2025, VOWST transaction-related obligations, and current operating plans, the Company expects to fund operations into the first quarter of 2026. The Company has implemented and continues to evaluate cost reduction actions aimed at extending its cash runway.